Passive Antibody Protection In The Setting Of Active Cel

主动细胞环境中的被动抗体保护

• 批准号: 6684226
• 负责人: John R Mascola
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6684226
• 关键词: AIDS vaccines; Macaca mulatta; cellular immunity; cytotoxic T lymphocyte; dosage; enzyme linked immunosorbent assay; human immunodeficiency virus 1; interleukin 2; neutralizing antibody; nonhuman therapy evaluation; passive immunization; vaccine development; vector vaccine

Current HIV vaccine candidates elicit reasonably potent cellular immune responses, but only low levels of neutralizing antibodies. Such CTL based vaccines (e.g., those based on DNA immunization) do not prevent infection, but can have a beneficial effect on disease course. In contrast, passively infused antibodies can provide complete protection, but must be administered in doses that result in serum antibody levels much higher than can be generated by current immunization strategies. In order to assess if CTL could combine with antibody to produce sterile immunity, we studied the effect of a suboptimal dose of neutralizing antibodies in animals with active immunity induced by IL2 adjuvanted DNA immunization. Using a SHIV-challenge model, this study has shown that passively infused antibody can protect against an intravenous challenge.

目前的HIV候选疫苗引起相当有效的细胞免疫应答，但仅产生低水平的中和抗体。这种基于CTL的疫苗（例如，基于DNA免疫的疫苗）不能预防感染，但对疾病进程有有益的影响。相反，被动输注的抗体可以提供完全保护，但必须以导致血清抗体水平远高于当前免疫策略产生的剂量施用。为了探讨CTL能否与抗体联合收割机结合产生无菌免疫，我们研究了次适剂量中和抗体对IL 2辅助DNA免疫诱导的主动免疫动物的影响。使用SHIV攻击模型，该研究表明被动输注抗体可以保护免受静脉内攻击。